SCHEDULE: Ikarian Capital Discloses 25.2% Stake in Quoin Pharma
Beneficial Ownership Report (Schedule 13G)
Ikarian Capital and Neil Shahrestani have reported a significant 25.2% beneficial ownership stake in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.
Summary
- Ikarian Capital, LLC and Neil Shahrestani (the "Reporting Persons") have jointly filed a Schedule 13G, disclosing beneficial ownership of Quoin Pharmaceuticals, Ltd. (the "Issuer").
- The Reporting Persons collectively beneficially own 211,538 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd.
- This ownership represents 25.2% of the Issuer's class of securities, based on 838,976 ADS outstanding as of November 3, 2025.
- The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separate managed accounts, for which Ikarian Capital serves as investment manager or sub-adviser.
- Neil Shahrestani indirectly controls Ikarian Capital and is therefore deemed to indirectly beneficially own the securities.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the Issuer.
Sentiment
Score: 6
Explanation: The disclosure of a significant beneficial ownership stake by an investment firm can be viewed as a vote of confidence, though the filing itself is purely factual and does not provide performance insights or forward-looking statements from the issuer.
Industry Context
This filing indicates a significant institutional investment in Quoin Pharmaceuticals, a company operating in the pharmaceutical sector. Such a large stake by an investment firm like Ikarian Capital could signal perceived value or strategic interest in the company's pipeline or market position within the broader pharmaceutical industry.
Stakeholder Impact
- Existing shareholders may see increased institutional interest in Quoin Pharmaceuticals due to the significant stake reported by Ikarian Capital and Neil Shahrestani, potentially influencing market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-11-03 | Date as of which 838,976 shares of ADS were outstanding, as disclosed in the Issuer's Prospectus. |
| 2025-11-30 | Date of event which requires the filing of this statement. |
| 2025-12-05 | Date the Issuer's Prospectus was filed with the U.S. Securities and Exchange Commission. |
| 2025-12-15 | Date the Schedule 13G statement was signed by Ikarian Capital, LLC and Neil Shahrestani. |
Keywords
Quoin Pharmaceuticals, Ikarian Capital, Neil Shahrestani, Beneficial Ownership, Schedule 13G, ADS, Investment Management, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.